As shown in figure 2A, wild type competitor duplex, but not mutant NF B competitor duplex was able to prevent Binimetinib RelA p65 from binding to the attached consensus sequence. RelA p65 specific siRNA knock down, whose efficacy was checked by immunoblotting, reduced RelA p65 binding activity by 50%. As shown in figure 2B, treatment with SAHA and to a lesser degree treatment with VPA resulted in a time dependent reduction of RelA p65 activity of up to 50%. In PANC 1 cells, 24 h of VPA treatment decreased RelA p65 activity by approximately 25%, however, this effect could not be intensified by extension of treatment periods and was not statistically significant. Although lesser effects were also seen for SAHA at shorter time points, a strong and significant RelA p65 inhibitory effect was only seen after 72 h.
As shown in figure 2A and 2B, treatment of cells with 8 M SAHA for 72 hours was able to diminish RelA p65 binding activity to the same degree as specific RelA p65 siRNA knockdown did. In addition, we found an influence of HDIs SAHA and VPA on the subcel lular localization of RelA p65 by exploratory immunoflu orescence analysis. The results of RelA p65 specific immunofluorescence are shown in figure 2. In untreated PANC 1 cells we observed a strong signal of RelA p65 predominantly in the nucleus. Both SAHA and, to a lesser degree VPA, led to a cytoplasmic retention of the protein after 72 h in stimulated cells. Both, SAHA and VPA did not affect protein levels of I B. Interestingly, phosphorylation of I B was notably inhib ited by both substances after 72 h of treatment.
In con trast, enhanced acetylation of histone H3 could be already observed after 12 h of HDI exposure. Discussion Our study, to our knowledge for the first time, displays a statistically significant in vivo correlation between class I HDAC isoform expression in pancreatic carcinoma and the presence of nuclear RelA p65, a protein known to be a key regulator in pancreatic carcinogenesis. Furthermore, Entinostat we could demonstrate that HDAC inhibitors are effective in inhibiting nuclear activation and binding capability of RelA p65 in pancreatic cancer cells. Although there is strong evidence that aberrant HDAC activity can contribute to the development of cancer, reports on isoform specific expression patterns of HDACs in tumor tissue are sparse. In line with previous studies of our group, which focussed on HDAC expression in malignancies of other organs like prostate and colon, pancreatic tumor tissue displayed a high degree of class I HDAC expression with HDAC3 being the most abundantly expressed isoform.